InflaRx (NASDAQ:IFRX) Now Covered by HC Wainwright

Key Points

• InflaRx (NASDAQ:IFRX) has received a buy rating from HC Wainwright, which has set a target price of $6.00, indicating a potential upside of 275% from its current stock price.
• Other analysts have shown mixed views, with Oppenheimer reducing its target from $6.00 to $3.00, while Raymond James lowered its rating to "outperform" with a $2.00 price target.
• InflaRx is currently well-supported by institutional investors, with 42.39% of its stock owned by hedge funds and institutional investors, highlighting interest in the company's clinical-stage biopharmaceutical developments.

HC Wainwright assumed coverage on shares of InflaRx (NASDAQ:IFRX - Free Report) in a report issued on Tuesday, MarketBeat reports. The firm issued a buy rating and a $6.00 price objective on the stock. HC Wainwright also issued estimates for InflaRx's Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.72) EPS.

Other analysts have also recently issued research reports about the company. Raymond James Financial cut InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price objective on the stock. in a report on Thursday, May 29th. Oppenheimer decreased their target price on InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research note on Thursday, May 29th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $6.20.

InflaRx Stock Up 5.1%

IFRX stock traded up $0.08 during midday trading on Tuesday, hitting $1.65. The company's stock had a trading volume of 764,609 shares, compared to its average volume of 764,250. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.82. The stock's 50-day moving average price is $0.96 and its 200 day moving average price is $1.14. The stock has a market cap of $110.76 million, a price-to-earnings ratio of -2.06 and a beta of 1.43.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.24) EPS for the quarter, meeting analysts' consensus estimates of ($0.24). The firm had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.02 million. As a group, equities analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IFRX. 683 Capital Management LLC increased its position in InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock valued at $2,678,000 after buying an additional 555,000 shares in the last quarter. Woodline Partners LP bought a new position in InflaRx during the 1st quarter valued at approximately $766,000. Northern Trust Corp increased its position in InflaRx by 1,933.1% during the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company's stock valued at $1,647,000 after buying an additional 634,045 shares in the last quarter. DAFNA Capital Management LLC bought a new position in InflaRx during the 1st quarter valued at approximately $459,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in InflaRx during the 2nd quarter valued at approximately $262,000. Hedge funds and other institutional investors own 42.39% of the company's stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.